Beauty's elevated efficacy movement now has another tool in its repertoire. Biotech firm Core Biogenesis has reportedly confirmed its oleosome-protein fusions are 10x more stable than conventional proteins and peptide-based actives, allowing for penetration deep into the dermis. According to the company, superior efficacy is the result.
The company, whose oleosome-protein fusions include Peauvita (FGF-2-oleosome) and Peauforia (EGF-oleosome), operates a plant biofactory greenhouse in Strasbourg, France.
There, biomimetic proteins and peptides are produced within Camelina sativa plants; these actives are then fused with naturally occurring spherical oleosome carriers comprising phospholipids, oil and vitamin E.
This fusion stabilizes the protein and peptide structures and facilitates deep delivery, as validated through skin explant studies conducted by the company.
“Traditionally, large peptides and proteins have struggled to penetrate the skin due to their size and instability,” says Alexandre Reeber, president and CEO of Core Biogenesis. “Our studies conclusively show that oleosome-protein fusions deliver actives to the dermis, while protein alone stops in the epidermis—a transformational result for the industry.”
The positive initial results have led the company to develop other proteins and peptides at its plant biofactory site.
“Beyond growth factors, we’ve successfully produced many proteins and peptides using our platform, addressing stability and delivery challenges that have limited innovation in the market,” says Tony Abboud, chief commercial officer (CCO) at Core Biogenesis. “This capability opens the door to co-developing next-generation actives with ingredient suppliers and brands for the personal care, health and wellness sectors.”
